Страна: Канада
Език: английски
Източник: Health Canada
DOXORUBICIN HYDROCHLORIDE
PFIZER CANADA ULC
L01DB01
DOXORUBICIN
2MG
SOLUTION
DOXORUBICIN HYDROCHLORIDE 2MG
INTRAVENOUS
5/25/100ML
Prescription
ANTINEOPLASTIC AGENTS
Active ingredient group (AIG) number: 0110825002; AHFS:
APPROVED
2013-08-16
_DOXORUBICIN (doxorubicin hydrochloride)_ _ _ _Page 1 of 30_ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION Pr DOXORUBICIN doxorubicin hydrochloride injection Solution, 2 mg/mL, for intravenous and intravesical use Antineoplastic agent Pfizer Canada ULC 17,300 Trans-Canada Highway Kirkland, Quebec H9J 2M5 Date of Initial Authorization: AUG 16, 2013 Date of Revision: NOV 25, 2022 Submission Control Number: 265420 © Pfizer Canada ULC 2022 _ _ _DOXORUBICIN (doxorubicin hydrochloride) - Product Monograph_ _ _ _Page 2 of 30_ RECENT MAJOR LABEL CHANGES 7 WARNINGS AND PRECAUTIONS, Reproductive Health: Female and Male Potential 11/2022 7 WARNINGS AND PRECAUTIONS, 7.1 Special Populations 11/2022 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED . RECENT MAJOR LABEL CHANGES ........................................................................................... 2 TABLE OF CONTENTS ............................................................................................................. 2 PART I: HEALTH PROFESSIONAL INFORMATION ..................................................................... 4 1 INDICATIONS .............................................................................................................. 4 1.1 Pediatrics ................................................................................................................... 4 1.2 Geriatrics ................................................................................................................... 4 2 CONTRAINDICATIONS ................................................................................................. 5 3 SERIOUS WARNINGS AND PRECAUTIONS BOX ............................................................ 5 4 DOSAGE AND ADMINISTRATION ................................................................................. 6 4.2 Recommended Dose and Dosage Adjustment ......................................................... 6 4.4 Administration ............... Прочетете целия документ